Evidio Domingo Musibay, MD
Medical Oncology · Minneapolis, MNNPI 1831321785
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Regeneron Healthcare Solutions, Inc. accounts for 61.6% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $34,515 and has fallen 99.8% since, to $69 in 2025.
Across 36 payments — averaging $1059.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$24K
- Sanofi$15K
- AstraZeneca$43
- Pfizer$26
Across 32 payments — averaging $7583.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$142K
- Sanofi US Services Inc.$47K
- Pfizer$19K
- E.r. Squibb & Sons, L.L.C.$16K
- Iovance Biotherapeutics, Inc.$8K
- Regeneron$6K
- plus $6K from 1 others
What the payments were for
- Consulting fees$10,84728%
- Speaking & faculty fees$21,54856%
- Travel & lodging$5,17514%
- Food & beverage$5071%
- Education$690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 15 | $23,516 |
| Sanofi | 19 | $14,561 |
| AstraZeneca | 1 | $43 |
| Pfizer | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIBTAYO$36,619
How this compares
$38,146 in reported general payments places this provider in the 80th percentile of 133 medical oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Imatinib Mesylate | 11 | $1,455 |
| Prochlorperazine Maleate | 21 | $197 |
| Ondansetron Hcl | 24 | $197 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Minneapolis
- Amy KrieMinneapolis$907K
- Emmanuel AntonarakisMinneapolis$260K
- Charles RyanMinneapolis$99K
- Dean GesmeMinneapolis$92K
- Robert KratzkeMinneapolis$79K
- Emil LouMinneapolis$11K
- Keith SkubitzMinneapolis$5K
- Alexandra RezazadehMinneapolis$3K
- Matthew NwaneriMinneapolis$3K
- Amit MahipalRochester$746K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.